Photys Therapeutics

Executive Summary

Photys Therapeutics is a private biotechnology company headquartered in Cambridge, MA, founded in 2021. The company is pioneering a new class of chimeric small molecules for precise control of protein function, leveraging three proprietary bifunctional platforms: PROTAC, tPRIME, and PHICS. These platforms induce proximity between target and effector biomolecules, enabling modulation of traditionally 'undruggable' targets. Photys focuses on oncology, autoimmune/inflammatory, and cardiometabolic diseases. The company has reached Phase 1 clinical stage, though no specific pipeline candidates are publicly detailed. Its differentiated platform technology positions it to address a wide range of disease targets with high therapeutic potential. The company's progress through early clinical development and its ability to generate proof-of-concept data will be key value drivers.

Upcoming Catalysts (preview)

• Q4 2026IND filing or Phase 1 initiation for lead oncology program70% success
• Q2 2026Presentation of preclinical data for tPRIME or PHICS platform at major conference (e.g., AACR 2026)85% success
• H2 2026Series B financing or major partnership announcement60% success